Focus on Mechanisms of Inflammation in Inflammatory Bowel Disease Sites of Inhibition: Current and Future Therapies

Gastroenterology Clinics of North America

Volumn 35, Issue 4, 2006, Pages 743-756

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3' (3 CYANOMORPHOLINO) 3' DEAMINODOXORUBICIN; ABT 874; ADALIMUMAB; BASILIXIMAB; CERTOLIZUMAB PEGOL; CNTO 1275; DACLIZUMAB; EPIDERMAL GROWTH FACTOR; FONTOLIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VISILIZUMAB;

ANTIINFLAMMATORY ACTIVITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; DRUG BINDING SITE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENTERITIS; GENETIC PREDISPOSITION; HUMAN; INFLAMMATORY INFILTRATE; INJECTION SITE REACTION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; AUTOANTIBODIES; BIOLOGICAL THERAPY; CELL ADHESION MOLECULES; CYTOKINES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, NATURAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; RECEPTORS, CYTOKINE;

EID: 33751215199     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.09.009     Document Type: Review

References (70)

1. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
2. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
4. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 9 (2004) 876-885
5. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
6. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
7. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
8. Franchimont D., Vermeire S., El Housni H., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
9. Wehkamp J., Fellermann K., Herrlinger K.R., et al. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 406-415
10. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
11. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
12. Hwang W.Y.K., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
13. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 4 (2005) 862-869
14. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
15. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
16. Youdim A., Vasiliauskas E.A., Targan S.R., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10 (2004) 333-338
17. Sandborn W.J., Hanauer S., Loftus Jr. E.V., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 10 (2004) 1984-1989
18. Hanauer S.B., Sandborn W.B., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastroenterology 130 (2006) 323-333
19. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the results of the CHARM trial. In: Programs and abstracts of the Digestive Disease Week, May 20-25, 2006. Los Angeles (CA): American Gastroenterology Association; 2006.
20. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 3 (2005) 807-818
21. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26 week placebo-controlled phase III study (PRECiSe 1). Gastroenterology 130 (2006) A107
22. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
23. ten Hove T., van Montfrans C., Peppelenbosch M.P., et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
24. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
25. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
26. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
27. Ringheanu M., Daum F., Markowitz J., et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 10 (2004) 801-810
28. Shen C., Van Assche G., Rutgeerts P., et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12 (2006) 22-28
29. Shen C., Van Assche G., Colpaert S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
30. Hlavaty T., Pierik M., Henckaerts L., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 22 7 (2005) 613-626
31. Mitoma H., Horiuchi T., Hatta N., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
32. Valencia X., Stephens G., Goldbach-Mansky R., et al. TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood 108 (2006) 253-261
33. Toubi E., Kessel A., Mahmudov Z., et al. Increased spontaneous apoptosis of CD4 + CD25 + T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 1051 (2005) 506-514
34. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200 (2004) 277-285
35. Suenaert P., Bulteel V., Lemmens L., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97 8 (2002) 2000-2004
36. Zeissig S., Bojarski C., Buergel N., et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53 9 (2004) 1295-1302 [erratum in Gut 2004;53(11):1722]
37. von Adrian U.H., and Mackay C.R. T-cell function and migration. N Engl J Med 343 (2000) 1020-1034
38. Ghosh S., Goldin E., Gordon F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
39. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 18 (2005) 1912-1925
40. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005) 2499-2507
41. Kunkel E.J., Ramos C.L., Steeber D.A., et al. The roles of L-selectin, beta 7 integrins and P-selectin in leukocyte rolling and adhesion in high endothelial venules of Peyer's patches. J Immunol 161 (1998) 2449-2456
42. Briskin M., Winsor-Hines D., Shyjan A., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 151 (1997) 97-110
43. Kuhlman P., Moy V.T., Lollo B.A., et al. The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. J Immunol 146 (1991) 1773-1782
44. Bridges L.C., Hanson K.R., Tani P.H., et al. The lymphocyte metalloprotease MDC-L (ADAM28) is a ligand for the integrin alpha4beta1. J Biol Chem 277 (2002) 3748-3792
45. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta 1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
46. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
47. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
48. Mannon P., Fuss I., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 352 (2004) 2069-2079
49. Reinisch W., Hommes D.W., Van Assche G., et al. A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease. Gut 55 (2006) 1138-1144
50. Hommes D.W., Mikhajlova T.L., Stoinov S., et al. Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut 55 (2006) 1131-1137
51. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
52. Plevy S., Salzberg B., Hommes D., et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 126 (2004) A75 [abstract]
53. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med 330 (1994) 1841-1845
54. D'Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120 (2001) 1323-1329
55. Willerford D.M., Chen J., Ferry J.A., et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid component. Immunity 3 (1995) 521-530
56. Poussier P., Ning T., Chen J., et al. Intestinal inflammation in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology 118 (2000) 880-891
57. Stallmach A., Wittig B., Giese T., et al. Protection of trinitrobenzene sulfonic acid-induced colitis by interleukin 2-IgG2b fusion protein in mice. Gastroenterology 117 (1999) 866-876
58. Kronenberg M., and Cheroutre H. Do mucosal T cells prevent intestinal inflammation?. Gastroenterology 118 (2000) 974-977
59. Maes B., and Vanrenterghem Y. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 14 (1999) 2824-2826
60. Chapman T.M., and Keating G.M. Basiliximab: a review of its use in induction therapy in renal transplantation. Drugs 63 (2003) 2803-2835
61. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Eng J Med 338 (1998) 161-165
62. Savo A.M., Book B.K., Henson S., et al. Daclizumab rapidly saturates interleukin-2-a (CD25) on lymph node lymphocytes in children. Transplant Proc 31 (1999) 1182-1183
63. Van Assche G., Dalle I., Noman M., et al. A pilot study on the use of the humanized anti interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 98 (2003) 369-376
64. Creed T.J., Norman M.R., Probert C.S., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18 1 (2003) 65-75
65. Van Assche G., Sandborn W.J., Feagan B.G., et al. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose- ranging trial. Gut 55 (2006) 1568-1574
66. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-interleukin-6 monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996
67. Beck P.L., and Podolsky D.K. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 5 1 (1999) 44-60
68. Sandborn W.J., Sands B.E., Wolf D.C., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 17 (2003) 1355-1364
69. Sinha A., Nightingale J., West K.P., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349 4 (2003) 350-357
70. Korzenik J.R., Dieckgraefe B.K., Valentine J.F., et al. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005) 2193-2201